Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

This review takes into consideration the principal vaccines developed against the SARS-
CoV-2 in this unprecedented period of Covid-19 pandemic. We evaluated the mechanism of …

The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory
syndrome coronavirus 2) that causes corona virus disease 2019 (COVID-19) and its impact …

Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in
clinical development and 173 are in the pre-clinical phase. Five types of vaccines are …

The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and
HCoV-19) has posed serious threats to public health and economic stability worldwide, thus …

The current coronavirus COVID-19 pandemic, which originated in Wuhan, China, has raised
significant social, psychological and economic concerns in addition to direct medical issues …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that belongs to
the coronavirus family and is the cause of coronavirus disease 2019 (COVID-19). As of May …

A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has
entered the human population and has spread rapidly around the world in the first half of …

COVID-19 is considered as the third human coronavirus and has a high potential for
transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine …

The emergence of the SARS‐CoV‐2 strain of the human coronavirus has thrown the world
into the midst of a new pandemic. In the human body, the virus causes COVID‐19, a disease …